Biffi A, Sabuncu MR, Desikan RS, et al. Genetic variation of oxidative phosphorylation genes in stroke and Alzheimer’s disease. Neurobiol Aging. 2014;35(8):1956.e1-8. doi:10.1016/j.neurobiolaging.2014.01.141
Hyman SE. Time for new schizophrenia Rx. Science. 2014;343(6176):1177. doi:10.1126/science.1252603
Bennett DA, Yu L, De Jager PL. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):617-30. doi:10.1016/j.bcp.2014.01.037
Radmanesh F, Devan WJ, Anderson CD, Rosand J, Falcone GJ, Alzheimer’s Disease Neuroimaging Initiative (ADNI). Accuracy of imputation to infer unobserved APOE epsilon alleles in genome-wide genotyping data. Eur J Hum Genet. 2014;22(10):1239-42. doi:10.1038/ejhg.2013.308
Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16(7):848-50. doi:10.1038/nn.3435
Raj T, Shulman JM, Keenan BT, et al. Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. Am J Hum Genet. 2012;90(4):720-6. doi:10.1016/j.ajhg.2012.02.022
Gräff J, Rei D, Guan JS, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483(7388):222-6. doi:10.1038/nature10849
Biffi A, Shulman JM, Jagiella JM, et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology. 2012;78(5):334-41. doi:10.1212/WNL.0b013e3182452b40
Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35. doi:10.1126/science.1132939
Yu L, Boyle PA, Nag S, et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol Aging. 2015;36(11):2946-53. doi:10.1016/j.neurobiolaging.2015.08.008